- Home
- VEON vs AKRO Comparison
VEON vs AKRO Comparison
Compare VEON & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEON
- AKRO
- Stock Information
- Founded
- VEON 1992
- AKRO 2017
- Country
- VEON United Arab Emirates
- AKRO United States
- Employees
- VEON N/A
- AKRO N/A
- Industry
- VEON Telecommunications Equipment
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- VEON Telecommunications
- AKRO Health Care
- Exchange
- VEON Nasdaq
- AKRO Nasdaq
- Market Cap
- VEON 3.8B
- AKRO 3.7B
- IPO Year
- VEON 1996
- AKRO 2019
- Fundamental
- Price
- VEON $51.44
- AKRO $46.15
- Analyst Decision
- VEON Strong Buy
- AKRO Strong Buy
- Analyst Count
- VEON 1
- AKRO 8
- Target Price
- VEON $60.00
- AKRO $80.38
- AVG Volume (30 Days)
- VEON 118.6K
- AKRO 1.2M
- Earning Date
- VEON 11-13-2025
- AKRO 11-07-2025
- Dividend Yield
- VEON N/A
- AKRO N/A
- EPS Growth
- VEON N/A
- AKRO N/A
- EPS
- VEON 13.63
- AKRO N/A
- Revenue
- VEON $4,148,000,000.00
- AKRO N/A
- Revenue This Year
- VEON $10.39
- AKRO N/A
- Revenue Next Year
- VEON $7.53
- AKRO N/A
- P/E Ratio
- VEON $3.83
- AKRO N/A
- Revenue Growth
- VEON 7.27
- AKRO N/A
- 52 Week Low
- VEON $29.29
- AKRO $21.34
- 52 Week High
- VEON $64.00
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- VEON 41.43
- AKRO 48.38
- Support Level
- VEON $51.10
- AKRO $45.72
- Resistance Level
- VEON $53.76
- AKRO $46.87
- Average True Range (ATR)
- VEON 2.10
- AKRO 1.71
- MACD
- VEON -0.23
- AKRO 0.17
- Stochastic Oscillator
- VEON 2.00
- AKRO 63.62
About VEON VEON Ltd. ADS
VEON Ltd is a United Arab Emirates-based digital operator providing connectivity and Internet services to corporations and individuals. The company offers mobile and fixed-line telecommunications services through a range of traditional and broadband mobile technologies. The company's reportable segments consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. It provides its services under the Beeline, Kyivstar, Banglalink, and Jazz brands. It generates the majority of its revenue from Pakistan.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.